Blood test shows promise for detecting breast cancer recurrence: Study
Patients who need cancer surgery are waiting longer for initial therapy, according to results of a retrospective cohort study.
A retrospective cohort of 150 breast‑cancer patients (105 primary, 45 recurrent) demonstrated that nucleosome‑based scores derived from cfDNA fragments (notably within the RERE and SYNPO2 loci) distinguish recurrent disease with an AUC of 0.826. Adding other cfDNA features in a machine‑learning model further improved recurrence prediction.
Early, non‑invasive detection of breast‑cancer recurrence can enable timely therapeutic intervention and personalized treatment, potentially improving survival and quality of life.
Bizonyítékszint: Korai humán adat. Kis vagy feltáró emberi adat.
Kapcsolódó jelek
- 20‑Year Risks of Breast‑Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
- Breast Cancer: The good, the bad, and an important call to effective risk reduction strategies
- Clinical Trials in Cancer - Transforming Clinical Research in the United States - NCBI Bookshelf
- Decoding Clinical Trials in Metastatic Breast Cancer: Practical Insights for Optimal Therapy Sequencing
- The SURVIVE study (NCT05658172): Bringing breast cancer aftercare to the 21st century: Study protocol of a Phase III clinical trial comparing liquid biopsy guided vs. Standard of care surveillance for intermediate to high-risk breast cancer survivors - PMC